Dacla® is a Direct-Acting Anti-viral (DAA) and is indicated in combination with other drugs for the treatment of chronic hepatitis C virus (HCV) infection in adults For activity in depending on the hepatitis C virus (HCV) genotype,
| DCI | DACLATASVIR |
|---|---|
| Dosage | 60 mg |
| Trade name | DACLA® |
| Name of the originator | DACLINSA® |
| Presentation | 28 tablets |
| Specialty | Hépatologie-AAD |
